INTRODUCTION: C-reactive protein (CRP) is a marker of cardiovascular disease (CVD). There is conflicting evidence regarding CRP as a marker of future cancer. We studied whether CRP predicts CVD and consecutive cancer in testicular cancer survivors (TCSs). PATIENTS AND METHODS: During 1998-2001, 586 TCSs with a high sensitivity CRP ≤ 10 mg/L were identified median 11 (4-21) years after treatment (FU-1). A second follow-up survey (FU-2) was conducted median 8 (6-9) years after FU-1. At FU-2 we obtained information about post-FU-1 CVD (cardiovascular death, nonfatal myocardial infarction, stroke, revascularisation or heart failure). Information about post-FU-1 non-germ cell cancer and cardiovascular death in all patients were retrieved from the Cancer Registry of Norway. RESULTS: After FU-1 31 (5.3%) of 586 patients developed non-germ cell cancer (excluding localised prostate cancer), while 28 (4.9%) developed CVD. Cox regression analyses showed that patients with CRP ≥1.5mg/L had 2.21 (95% CI 1.04-4.70) times higher risk of developing non-germ cell cancer and 2.79 (95% CI 1.22-6.34) times higher risk for CVD compared to patients with CRP <1.5mg/L at FU-1. CONCLUSION: In long-term TCSs, CRP may serve as a potential marker of cardiovascular events and a second cancer.
INTRODUCTION:C-reactive protein (CRP) is a marker of cardiovascular disease (CVD). There is conflicting evidence regarding CRP as a marker of future cancer. We studied whether CRP predicts CVD and consecutive cancer in testicular cancer survivors (TCSs). PATIENTS AND METHODS: During 1998-2001, 586 TCSs with a high sensitivity CRP ≤ 10 mg/L were identified median 11 (4-21) years after treatment (FU-1). A second follow-up survey (FU-2) was conducted median 8 (6-9) years after FU-1. At FU-2 we obtained information about post-FU-1 CVD (cardiovascular death, nonfatal myocardial infarction, stroke, revascularisation or heart failure). Information about post-FU-1 non-germ cell cancer and cardiovascular death in all patients were retrieved from the Cancer Registry of Norway. RESULTS: After FU-1 31 (5.3%) of 586 patients developed non-germ cell cancer (excluding localised prostate cancer), while 28 (4.9%) developed CVD. Cox regression analyses showed that patients with CRP ≥1.5mg/L had 2.21 (95% CI 1.04-4.70) times higher risk of developing non-germ cell cancer and 2.79 (95% CI 1.22-6.34) times higher risk for CVD compared to patients with CRP <1.5mg/L at FU-1. CONCLUSION: In long-term TCSs, CRP may serve as a potential marker of cardiovascular events and a second cancer.
Authors: Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice Journal: J Natl Cancer Inst Date: 2012-02-06 Impact factor: 13.506
Authors: Maha I Alkhalaf; Wafa S Alansari; Fawzia A Alshubaily; Afnan M Alnajeebi; Areej A Eskandrani; Manal A Tashkandi; Nouf A Babteen Journal: Sci Rep Date: 2020-07-28 Impact factor: 4.379
Authors: Mette Sprauten; Thomas H Darrah; Derick R Peterson; M Ellen Campbell; Robyn E Hannigan; Milada Cvancarova; Clair Beard; Hege S Haugnes; Sophie D Fosså; Jan Oldenburg; Lois B Travis Journal: J Clin Oncol Date: 2011-12-19 Impact factor: 44.544
Authors: Sara Bleve; Maria Concetta Cursano; Chiara Casadei; Giuseppe Schepisi; Cecilia Menna; Milena Urbini; Caterina Gianni; Silvia De Padova; Alessia Filograna; Valentina Gallà; Giovanni Rosti; Domenico Barone; Michal Chovanec; Michal Mego; Ugo De Giorgi Journal: Front Oncol Date: 2022-06-10 Impact factor: 5.738
Authors: A Terbuch; F Posch; L M Annerer; T Bauernhofer; M Pichler; J Szkandera; G C Hutterer; K Pummer; R Partl; K S Kapp; H Stöger; A Gerger; M Stotz Journal: Clin Transl Oncol Date: 2017-08-29 Impact factor: 3.405